OPTI and OPTH Related Headlines
Go Back- Optimi Health completes psilocybin batch for trial and Australia supply
- Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
- Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
- Optimi Health plans Phase 3 MDMA-assisted therapy trial for PTSD
- Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
- Optimi Health to start Phase 2 psilocybin trial for depression
- Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
- Optimi Health Establishes Discretionary Equity Facility
- Optimi Health ships psilocybin capsules to Australia in third export
- Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
- Optimi Health ships psilocybin capsules to Australia in third export
- Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
- Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
- OPTIMI Health adds 1mg and 2mg psilocybin doses for clinical research
- Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
- Optimi Health exports psilocybin to UK for phase 2 clinical trial
- Optimi Health ships first psilocybin export to UK for phase 2 trial
- Optimi Health exports psilocybin to UK for phase 2 clinical trial
- Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
- Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
- Australia expands psychedelic therapy access with updated prescriber rules
- Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
- Optimi Health prices $15 million offering, lists on NASDAQ
- Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
OPTI and OPTH Related Press Releases
Go Back- Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
- Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
- Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
- Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
- Optimi Health Establishes Discretionary Equity Facility
- Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
- Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
- Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
- Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
- Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
- Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
- Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
- Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
